CAS: 20826-04-4; 3-Bromo-5-Pyridine Carboxylic Acid

上下游产品

CAS号10400-19-8 烟酰氯 | CAS号27848-84-6 尼麦角林 | CAS号29681-44-5 5-溴烟酸甲酯 | CAS号5332-24-1 3-溴喹啉 | CAS号59-67-6 烟酸 | CAS号625-92-3 3,5-二溴吡啶 | CAS号3430-16-8 3-溴-5-甲基吡啶 | CAS号98555-51-2 5-溴吡啶-2,3-二羧酸 | CAS号342013-81-4 5-溴-3-吗啉甲酰基吡啶 | CAS号342013-78-9 5-溴-N-叔丁基烟酰胺 | CAS号494-97-3 原烟碱 | CAS号385382-48-9 5-溴-N-环丙基烟酰胺 | CAS号36052-25-2 5-氨基吡啶-3-羧酸甲酯 | CAS号491588-98-8 5-溴-4-碘吡啶-3-羧酸 | CAS号39620-02-5 5-溴吡啶-3-羰酰氯 | CAS号39741-46-3 3-溴-5-(氯甲基)吡啶盐酸盐 | CAS号38940-62-4 3-溴-5-乙酰基吡啶 | CAS号342013-85-8 5-溴-n-环己基烟酰胺

3,5-二溴吡啶置于正丁基锂,乙醚体系中,化学反应生成5-溴烟酸
参考文献:Pyridyllithium Compounds
标题:Pyridyllithium Compounds
摘要:
Doi:10.1021/jo50003A022

专利信息

专利号:US-2006116519-A1
优先权日:2004-11-17
标 题:Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
发明人：MA CHUNRONG; TIAN QINGPING
权利人:AGOURON PHARMA
摘要:The present invention relates to novel synthetic methods for the preparation of intermediates of 3{5-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]4-methyl-pyridin-3-yl methyl}-ethyl-amine.

专利号:US-9549917-B2
优先权日:2011-09-08
标 题 :Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
发明人：MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; LAI ZHONG; DANG QUN; ZORN NICOLAS
权利人:MCCOMAS CASEY C; LIVERTON NIGEL J; HABERMANN JOERG; KOCH UWE; NARJES FRANK; LI PENG; PENG XUANJIA; SOLL RICHARD; WU HAO; PALANI ANANDAN; DAI XING; LIU HONG; HE SHUWEN; LAI ZHONG; DANG QUN; ZORN NICOLAS; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-9549921-B2
优先权日:2013-06-24
标 题:Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
发明人：HE SHUWEN; LAI ZHONG; DAI XING; XIAO DONG; LONDON CLARE; ZORN NICOLAS; NARGUND RAVI; PALANI ANANDAN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD
权利人:HE SHUWEN; LAI ZHONG; DAI XING; XIAO DONG; LONDON CLARE; ZORN NICOLAS; NARGUND RAVI; PALANI ANANDAN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:EP-3515880-B1
优先权日:2017-03-17
标题:Methods and compositions for synthesis of encoded libraries
发明人：LI JIN; MORGAN BARRY A; Wan jinqiao; DOU DENGFENG; LIU GUANSAI; CHANG YONG; CHEN QIUXIA; WANG XING; XU YANSHAN; HU DONGYAN; LIU JIAN; CHENG XUEMIN
权利人:HITGEN INC

专利号:US-2020149034-A1
优先权日:2017-03-17
标题:Methods and Compositions for Synthesis of Encoded Libraries